(Q48199565)

English

Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins.

scientific article published on 29 January 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17439900

Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins. (English)

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17439900

multiple sclerosis

0 references

author name string

Sarchielli P

1

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17439900

Zaffaroni M

2

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17439900

Floridi A

3

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17439900

Greco L

4

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17439900

Candeliere A

5

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17439900

Mattioni A

6

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17439900

Tenaglia S

7

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17439900

Di Filippo M

8

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17439900

Calabresi P

9

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17439900

publication date

29 January 2007

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17439900

Multiple Sclerosis Journal

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17439900

13

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17439900

3

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17439900

313-331

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17439900

Physiological approaches to neuroprotection. boosting of protective autoimmunity

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Neuronal control of the immune response in the central nervous system: linking brain immunity to neurodegeneration.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Mast cells differentially express and release active high molecular weight neurotrophins

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

The neuroprotective role of inflammation in nervous system injuries.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Brain-derived neurotrophic factor

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Brain-derived neurotrophic factor controls dopamine D3 receptor expression: therapeutic implications in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Pathogenesis of Parkinson's disease: prospects of neuroprotective and restorative therapies.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Brain-derived neurotrophic factor as a drug target for CNS disorders

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Physiology of the neurotrophins

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Cellular sources of enhanced brain-derived neurotrophic factor production in a mouse model of allergic inflammation.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

The cognitive paradigm and the immunological homunculus

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Brain-derived neurotrophic factor in patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Increased brain-derived neurotrophic factor expression in white blood cells of relapsing-remitting multiple sclerosis patients.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Neurotrophic factors and clinical recovery in relapsing-remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Effect of immunomodulatory drugs on in vitro production of brain-derived neurotrophic factor.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factorin situ

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Defining the clinical course of multiple sclerosis: Results of an international survey

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Sensitivity and reproducibility of volume change measurements of different brain portions on magnetic resonance imaging in patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Combined treatment of glatiramer acetate and low doses of immunosuppressive drugs is effective in the prevention of graft rejection

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

In vitro evidence that subcutaneous administration of glatiramer acetate induces hyporesponsive T cells in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Transport of brain-derived neurotrophic factor across the blood-brain barrier.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Can glatiramer acetate reduce brain atrophy development in multiple sclerosis?

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070146

21 January 2018

Identifiers

10.1177/1352458506070146

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17439900

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/17439900

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48199565&oldid=852444222"